Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Current Liabilities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Total Current Liabilities for 6 consecutive years, with $25.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 49.58% to $25.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.6 million through Dec 2025, down 49.58% year-over-year, with the annual reading at $25.6 million for FY2025, 49.58% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $25.6 million at Relay Therapeutics, down from $32.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $71.6 million in Q2 2023, with the low at $16.1 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $42.3 million, with a median of $39.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 161.95% in 2022, then tumbled 52.49% in 2023.
  • Over 5 years, Total Current Liabilities stood at $24.3 million in 2021, then soared by 161.95% to $63.7 million in 2022, then crashed by 52.49% to $30.3 million in 2023, then soared by 67.59% to $50.7 million in 2024, then crashed by 49.58% to $25.6 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $25.6 million, $32.6 million, and $32.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.